Wedbush lowered the firm’s price target on Geron (GERN) to $6 from $7 and keeps an Outperform rating on the shares following quarterly results. Based on the firm’s discussion with management, Wedbush believes both a lack of awareness of Rytelo overall, and an apparent wariness of cytopenias associated with Rytelo treatment are key issues for uptake – the firm sees these issues as fixable with recent HCP education efforts.
Confident Investing Starts Here:
- Quickly and easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks straight to you inbox with TipRanks' Smart Value Newsletter
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on GERN:
- Scotiabank downgrades Geron to Sector Perform on Rytelo launch challenges
- Geron downgraded to Sector Perform from Outperform at Scotiabank
- Geron Corporation’s Q1 2025 Financial Highlights
- Geron Corporation’s Earnings Call: Mixed Sentiments and Strategic Moves
- Positive Growth Prospects for Geron Amid Strategic Expansion and Strong Financial Position